Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure
First of several studies to investigate the potential of BRII-179 in...

Related Keywords

China ,Hong Kong ,Beijing ,Shanghai ,Brii Bio ,Asia Pacific ,Nasdaq ,Brii Biosciences ,National Medical Products Administration ,Vir Biotechnology Inc ,Prnewswire Brii Biosciences Limited Bio ,Drug Administration ,Brii Biosciences Limited Bio ,Vaccines Inc ,Biosciences Limited ,Greater China ,Market Authorization Application ,Vir Biotechnology ,Investigational New Drug ,Drug Evaluation ,San Francisco Bay Area ,Markets ,